Loading clinical trials...
Loading clinical trials...
A First in Human Phase 1 / 2 Multi-center Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of CTx001 Administered Via a Single Subretinal Injection in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
Conditions
Interventions
CTx001
Locations
3
United States
Midwest Eye Institute
Carmel, Indiana, United States
Sierra Eye Associates
Reno, Nevada, United States
Retina Foundation of the Southwest
Dallas, Texas, United States
Start Date
December 30, 2025
Primary Completion Date
May 31, 2028
Completion Date
June 30, 2032
Last Updated
March 17, 2026
NCT06990269
NCT07424235
Lead Sponsor
Complement Therapeutics
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions